The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Slides:

Advertisements

Similar presentations

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Advertisements

Operative outcomes in mitral valve surgery: Combined effect of surgeon and hospital volume in a population-based analysis Arman Kilic, MD, Ashish S.

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Of mice and men and surgical transcatheter aortic valve insertion

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study Vincent Chan,

A wolf in sheep's clothing

Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R

Reoperative aortic valve replacement in the octogenarians—minimally invasive technique in the era of transcatheter valve replacement Tsuyoshi Kaneko,

In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.

Fate of aortic bioprostheses: An 18-year experience

Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E

Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards.

Long-term prognosis of ascending aortic aneurysm after aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis Evaldas Girdauskas,

When is the Ross operation a good option to treat aortic valve disease? Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc

Aortic valve replacement: Results and predictors of mortality from a contemporary series of 2256 patients Marco Di Eusanio, MD, PhD, Daniela Fortuna,

Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society.

Mitral mechanical replacement in young rheumatic women: Analysis of long-term survival, valve-related complications, and pregnancy outcomes over a 3707-patient-year.

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age Torsten Christ,

Aortic root remodeling leads to good valve stability in acute aortic dissection and preexistent root dilatation Takashi Kunihara, MD, PhD, Niklas Neumann,

Surgical therapy for ischemic heart failure: Single-center experience with surgical anterior ventricular restoration Lorenzo Menicanti, MD, Serenella.

Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against.

Form ever follows function

Reoperative “valve-in-valve” transapical transcatheter mitral valve replacement in a high-risk patient with a recent transapical transcatheter aortic.

Bicuspid aortic valve aortopathy: One size fits all?

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

Quality of mitral valve surgery at the United States Department of Veterans Affairs Juan A. Crestanello, MD The Journal of Thoracic and Cardiovascular.

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Transcatheter aortic valve replacement in intermediate-risk patients

Finite element analysis for transcatheter aortic valve replacement: More than a seer reading the future! Michele Di Mauro, MD, Luca Paolo Weltert, MD,

Structural deterioration of the Freestyle aortic valve: Mode of presentation and mechanisms Siamak Mohammadi, MD, Richard Baillot, MD, Pierre Voisine,

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Michele Gallo, MD, Gino Gerosa, MD

Age alone should not preclude surgery: Contemporary outcomes after aortic valve replacement in nonagenarians Isaac George, MD, Halit Yerebakan, MD, Bindu.

Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration.

Midterm results of Manouguian double valve replacement: Comparison with standard double valve replacement Hiroshi Okuyama, MD, Kazuhiro Hashimoto, MD,

Role of the sinuses of Valsalva on the opening of the aortic valve

The Journal of Thoracic and Cardiovascular Surgery

Intraaortic Migration of an Epicardial Pacing Wire: Percutaneous Extraction Lorenzo Guerrieri Wolf, MD, Raffaele Scaffa, MD, Daniele Maselli, MD, Luca.

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Niv Ad, MD, Lawrence M. Wei, MD

Replicating the success of mitral valve repair in the aortic valve

Commentary: Bioprosthetic aortic valve replacement: A high standard of comparison for transcatheter aortic valve implantation Aaron Martin, MD, Michael.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Sutureless valve implantation: Every detail counts

The Mitroflow aortic valve: A past, present, and future illuminated

Hans-Joachim Schäfers, MD

Quality of life after aortic valve surgery: Replacement versus reconstruction Diana Aicher, MD, Annika Holz, Susanne Feldner, MD, Volker Köllner, MD,

Long-term results of Freestyle stentless bioprosthesis in the aortic position: A single- center prospective cohort of 500 patients Nicolas Amabile, MD,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

Acute aortic dissection: The conundrum of severity of disease, extent of surgery and end-organ function Luca Salvatore De Santo, MD, FESC The Journal.

Commentary: When a choice is not an echo

Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement Todd M. Dewey,

Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position Amedeo Anselmi, MD, Erwan Flécher, MD, PhD, Vito Giovanni Ruggieri,

“The more things change…”: The challenges ahead

Racing to the Rubicon Michael J. Reardon, MD, Vinod H. Thourani, MD

National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements Abby J. Isaacs, MS, Jeffrey Shuhaiber,

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Durability of pericardial versus porcine bioprosthetic heart valves

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Lessons learned from Melody valve retrieved at transplantation

Fate of functional tricuspid regurgitation in aortic stenosis after aortic valve replacement Dong Seop Jeong, MD, PhD, Kiick Sung, MD, PhD, Wook Sung.

Paul Philipp Heinisch, MD, Thierry Carrel, MD

Negative pressure wound treatment improves Acute Physiology and Chronic Health Evaluation II score in mediastinitis allowing a successful elective pectoralis.

Presentation transcript:

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario, MD, Andrea Salica, MD, Luca P. Weltert, MD, Raffaele Scaffa, MD, Lorenzo Guerrieri Wolf, MD, Daniele Maselli, MD, Michele Di Mauro, MD The Journal of Thoracic and Cardiovascular Surgery Volume 153, Issue 1, Pages 31-39.e2 (January 2017) DOI: 10.1016/j.jtcvs.2016.08.063 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Mean transprosthetic gradient average values and outliers in longitudinal echocardiography surveillance. *P < .05 versus discharge. The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Overall survival and patients at risk in the whole patient population divided by size 19- or 21-mm Mitroflow valve prostheses (LivaNova, London, United Kingdom). The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Cardiac- and valve-related mortality and patients at risk, for the operative survivors. The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Freedom from reoperation because of structural valve deterioration (SVD) and patients at risk, for the operative survivors. AVR, Aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Freedom from structural valve deterioration (SVD) (as defined by a mean gradient > 35 mm Hg) and patients at risk, for the operative survivors. The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 6 Freedom from structural valve deterioration (SVD) (as defined by a mean gradient >35 mm Hg) and patients at risk, for the operative survivors, divided by the 2 sizes of implanted Mitroflow valve prostheses (LivaNova, London, United Kingdom). The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Nomogram of time from implant expected freedom from structural valve deterioration (SVD) stratified by age-class. The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Freedom from structural valve deterioration in 19- and 21-mm Mitroflow valve prostheses (LivaNova, London, United Kingdom). The Journal of Thoracic and Cardiovascular Surgery 2017 153, 31-39.e2DOI: (10.1016/j.jtcvs.2016.08.063) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions